Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
LGVN
LGVN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LGVN News
Longeveron Announces Phase 2a Data Presentation for Alzheimer's Therapy
2d ago
Newsfilter
Longeveron Receives EMA SME Designation for Drug Development
Jun 09 2026
Newsfilter
Longeveron Highlights New Data on Stem Cell Therapy
Jun 04 2026
Newsfilter
Longeveron Q1 2026 Earnings Call Insights
May 14 2026
seekingalpha
Longeveron Advances Phase 2b Trial for HLHS
May 11 2026
Newsfilter
Longeveron Advances FDA Discussions on ELPIS II Trial
May 11 2026
NASDAQ.COM
FDA Raises Concerns Over Longeveron's Cell Therapy Trial Design
May 09 2026
stocktwits
Longeveron Discusses ELPIS II with FDA
May 08 2026
Newsfilter
Avaí Bio Advances Anti-Aging Therapeutics Development
Apr 23 2026
Globenewswire
Avaí Bio Advances Longevity Therapeutics Development
Apr 23 2026
Newsfilter
Avaí Bio Advances Cell Therapy for Aging
Apr 10 2026
PRnewswire
Avaí Bio and Austrianova Advance Anti-Aging Therapy Collaboration
Apr 10 2026
Newsfilter
Longeveron Secures Patent for Potency Assay Methods in China
Apr 08 2026
Newsfilter
LONGEVERON RECEIVES CHINESE PATENT FOR METHODS TO ASSESS POTENCY OF HUMAN MESENCHYMAL STEM CELLS (MSCS)
Apr 08 2026
moomoo
Avaí Bio Initiates Production of α-Klotho Cell Bank
Mar 18 2026
Globenewswire
Avaí Bio Initiates Production of α-Klotho Cells
Mar 18 2026
PRnewswire
Show More News
